NASDAQ:SXTP 60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free SXTP Stock Alerts $0.24 +0.01 (+4.35%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.23▼$0.2450-Day Range$0.23▼$0.3252-Week Range$0.22▼$8.65Volume84,376 shsAverage Volume290,194 shsMarket Capitalization$2.78 millionP/E RatioN/ADividend YieldN/APrice Target$2.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get 60 Degrees Pharmaceuticals alerts: Email Address 60 Degrees Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside900.0% Upside$2.40 Price TargetShort InterestHealthy1.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.29) to ($0.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.14 out of 5 stars 3.3 Analyst's Opinion Consensus Rating60 Degrees Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst Coverage60 Degrees Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.50% of the float of 60 Degrees Pharmaceuticals has been sold short.Short Interest Ratio / Days to Cover60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 60 Degrees Pharmaceuticals has recently increased by 95.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield60 Degrees Pharmaceuticals does not currently pay a dividend.Dividend Growth60 Degrees Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SXTP. Previous Next 1.1 News and Social Media Coverage News Sentiment60 Degrees Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for 60 Degrees Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for SXTP on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($0.29) to ($0.12) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.Read More SXTP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SXTP Stock News HeadlinesApril 18, 2024 | msn.com60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 8.33% to 1.33April 3, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisMarch 14, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024February 20, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 20, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.January 31, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingJanuary 31, 2024 | finance.yahoo.comWallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingJanuary 30, 2024 | marketwatch.com60 Degrees Shares Plumb New Lows After Public OfferingJanuary 30, 2024 | morningstar.com60 Degrees Pharmaceuticals IncJanuary 30, 2024 | finance.yahoo.comWallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingJanuary 30, 2024 | markets.businessinsider.comWhy Is 60 Degrees (SXTP) Stock Down 33% Today?January 30, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingJanuary 22, 2024 | msn.com60 Degrees Pharmaceuticals files to sell 4.79M unitsJanuary 22, 2024 | msn.comWhy Is 60 Degrees Pharmaceuticals Stock Trading Higher Today?January 22, 2024 | marketwatch.com60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDAJanuary 22, 2024 | finance.yahoo.com60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingJanuary 16, 2024 | finance.yahoo.com60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsDecember 28, 2023 | marketwatch.com60 Degrees Pharmaceuticals Shares Surge 28% on Approved Study of Tafenoquine as Potential Bbesiosis TreatmentDecember 26, 2023 | msn.comWhy Is Infection Treatment Focused-60 Degrees Pharmaceuticals Stock Soaring Today?December 26, 2023 | finance.yahoo.com60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024November 15, 2023 | msn.com60 Degrees to meet with FDA over developing Arakoda for babesiosisNovember 15, 2023 | sg.finance.yahoo.com60 Degrees Pharmaceuticals, Inc. (SXTP)November 15, 2023 | finance.yahoo.com60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseSee More Headlines Receive SXTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/27/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SXTP CUSIPN/A CIK1946563 Web60degreespharma.com Phone202-327-5422FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$2.40 High Stock Price Target$2.40 Low Stock Price Target$2.40 Potential Upside/Downside+900.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.39 Sales & Book Value Annual Sales$250,000.00 Price / Sales11.11 Cash FlowN/A Price / Cash FlowN/A Book Value($0.87) per share Price / Book-0.28Miscellaneous Outstanding Shares11,570,000Free FloatN/AMarket Cap$2.78 million OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Geoffrey Stuart Dow (Age 50)Chairman, CEO & President Comp: $125.56kMr. Tyrone Miller (Age 49)CFO & Director Comp: $135.63kDr. Bryan Smith (Age 58)Chief Medical Officer Ms. Kristen LandonChief Commercial OfficerMs. Jennifer HerzDirectorKey CompetitorsAraviveNASDAQ:ARAVAridis PharmaceuticalsNASDAQ:ARDSAgile TherapeuticsNASDAQ:AGRXOnconetixNASDAQ:ONCOTransCode TherapeuticsNASDAQ:RNAZView All CompetitorsInstitutional OwnershipCentral Bank & Trust Co.Sold 89,000 shares on 4/11/2024Ownership: 4.613%View All Institutional Transactions SXTP Stock Analysis - Frequently Asked Questions Should I buy or sell 60 Degrees Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 60 Degrees Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SXTP shares. View SXTP analyst ratings or view top-rated stocks. What is 60 Degrees Pharmaceuticals' stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for 60 Degrees Pharmaceuticals' stock. Their SXTP share price targets range from $2.40 to $2.40. On average, they anticipate the company's share price to reach $2.40 in the next year. This suggests a possible upside of 900.0% from the stock's current price. View analysts price targets for SXTP or view top-rated stocks among Wall Street analysts. How have SXTP shares performed in 2024? 60 Degrees Pharmaceuticals' stock was trading at $1.02 at the start of the year. Since then, SXTP stock has decreased by 76.5% and is now trading at $0.24. View the best growth stocks for 2024 here. Are investors shorting 60 Degrees Pharmaceuticals? 60 Degrees Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 130,700 shares, an increase of 95.1% from the March 31st total of 67,000 shares. Based on an average daily trading volume, of 335,700 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.5% of the company's shares are sold short. View 60 Degrees Pharmaceuticals' Short Interest. When is 60 Degrees Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our SXTP earnings forecast. How were 60 Degrees Pharmaceuticals' earnings last quarter? 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) issued its earnings results on Monday, April, 1st. The company reported ($0.44) earnings per share for the quarter. The firm earned ($0.10) million during the quarter, compared to analysts' expectations of $0.06 million. When did 60 Degrees Pharmaceuticals IPO? 60 Degrees Pharmaceuticals (SXTP) raised $7 million in an initial public offering (IPO) on Wednesday, July 12th 2023. The company issued 1,400,000 shares at a price of $5.30 per share. WallachBeth Capital LLC acted as the underwriter for the IPO. Who are 60 Degrees Pharmaceuticals' major shareholders? 60 Degrees Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Central Bank & Trust Co. (4.61%). How do I buy shares of 60 Degrees Pharmaceuticals? Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SXTP) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryYou Won't Believe Who Bezos is Working With to Fight Alzheimer'sBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
